POINT logo light blue (png).png
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
29 nov. 2022 07h30 HE | POINT Biopharma
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
Laboratory Animal Diet Global Market Report 2022: Rising Use of Mice in Virology and Infectious Disease Research Drives Growth
25 nov. 2022 08h23 HE | Research and Markets
Dublin, Nov. 25, 2022 (GLOBE NEWSWIRE) -- The "Laboratory Animal Diet Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diet Type, Animal, Application and End User" report has been...
Global Real World Evidence Solutions Market Report 2022: Increased R&D Spending for the Development of New Pharmaceutical Products and Medical Devices Drives Sector
17 nov. 2022 08h53 HE | Research and Markets
Dublin, Nov. 17, 2022 (GLOBE NEWSWIRE) -- The "Global Real World Evidence Solutions Market by Component (Services, Disparate Data Sets, (Claims, Clinical, Pharmacy, Patient), Application (Oncology,...
22157.jpg
China Bispecific Antibody Market Opportunity & Clinical Trials Insights to 2028: Opportunity, Regulatory Affairs, Marketed Bispecific Antibodies, Bispecific Antibodies Available For Licensing
17 nov. 2022 06h20 HE | Research and Markets
Dublin, Nov. 17, 2022 (GLOBE NEWSWIRE) -- The "China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. At...
22157.jpg
Global Non-Animal Alternative Testing Market Report to 2030 - Featuring Evotec, Biovit, MB Research Laboratories, Emulate and TARA Biosystems Among Others
16 nov. 2022 07h43 HE | Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "Non-Animal Alternative Testing Market By Technology, By Method, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has...
Clinical Trial Supplies Global Market Report 2022: Increasing Number of Registered Clinical Trials Boosts Sector
15 nov. 2022 07h18 HE | Research and Markets
Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics), Phases (I to IV), Type (Small Molecules, Biologics), Therapeutic...
POINT logo light blue (png).png
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
14 nov. 2022 07h15 HE | POINT Biopharma
INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
14 nov. 2022 07h00 HE | POINT Biopharma
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
$2.72 Billion Worldwide Mice Model Industry to 2027 - Featuring Allentown, Cyagen Biosciences, Envigo and Fengshi Among Others
10 nov. 2022 04h43 HE | Research and Markets
Dublin, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The "Global Mice Model Market (2022-2027) by Type, Services, Technology, Mice Care Products, Applications, and Geography, Competitive Analysis and the...
DynamiCure Logo.png
DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers
08 nov. 2022 11h11 HE | DynamiCure Biotechnology, LLC
The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in...